The New England Journal of Medicine December 13, 2012

Reduction in Inappropriate Therapy and Mortality through ICD Programming

Arthur J. Moss, Claudio Schuger, Christopher A. Beck et al.

Bottom Line

In patients with a primary-prevention indication for an ICD, programming the device with a high-rate cutoff or a delayed-therapy approach significantly reduced the risk of inappropriate therapies and all-cause mortality compared to conventional programming.

Key Findings

1. High-rate therapy significantly reduced the first occurrence of inappropriate therapy compared to conventional programming (4% vs. 20%; Hazard Ratio [HR] 0.21, 95% CI 0.13-0.34, P<0.001).

2. Delayed therapy also significantly reduced the first occurrence of inappropriate therapy compared to conventional programming (5% vs. 20%; HR 0.24, 95% CI 0.15-0.40, P<0.001).

3. All-cause mortality was significantly lower in the high-rate therapy arm (3.2%) compared to the conventional programming arm (6.6%) (HR 0.45, 95% CI 0.24-0.85, P=0.01).

4. First occurrence of appropriate therapy was also lower in the high-rate (9%) and delayed-therapy (6%) arms compared with the conventional arm (22%), primarily due to a significant reduction in unnecessary anti-tachycardia pacing.

5. There were no significant differences in the incidence of first syncope among the three groups (approximately 4.4% to 4.5% across all arms).

Study Design

Design

Randomized Controlled Trial

Single-Blind

Sample

1,500

Patients

Duration

1.4 yr

Median

Setting

Multicenter, international

Population Patients with ischemic or nonischemic cardiomyopathy who met criteria for a primary-prevention implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRT-D).

Intervention High-rate therapy (single ventricular tachycardia therapy zone ≥200 bpm with a 2.5-second delay) OR Delayed therapy (ventricular tachycardia zone ≥170 bpm with a 60-second delay for 170-199 bpm, 12-second delay for 200-249 bpm, and 2.5-second delay for ≥250 bpm).

Comparator Conventional programming (ventricular tachycardia zone ≥170 bpm with a 2.5-second delay for 170-199 bpm and a 1.0-second delay for ≥200 bpm).

Outcome The first occurrence of inappropriate ICD therapy (anti-tachycardia pacing or shock).

Study Limitations

• The trial was stopped early and had a relatively short average follow-up of only 1.4 years, which limits the assessment of long-term safety and survival benefits.

• The study excluded secondary-prevention patients (those with a history of sustained VT/VF or cardiac arrest), meaning the findings are strictly applicable only to primary-prevention populations.

• Due to the nature of device programming, the trial was single-blind; while patients were blinded, the electrophysiologists managing the devices were aware of the assigned group, introducing potential bias in clinical decision-making.

• The programming specifics used a standardized approach that may require complex translation across different proprietary device manufacturer algorithms.

Clinical Significance

The MADIT-RIT trial revolutionized ICD programming by demonstrating that a 'less is more' strategy—using higher heart-rate cutoffs (≥200 bpm) or prolonged detection delays—drastically prevents inappropriate shocks and unnecessary anti-tachycardia pacing. Notably, this reduction in excessive therapy translated to a clinically significant survival benefit, solidifying conservative programming as the standard of care for primary prevention ICDs.

Historical Context

Prior to MADIT-RIT, ICDs were generally programmed with relatively low heart-rate thresholds (e.g., 170 bpm) and short detection intervals to quickly terminate potentially lethal ventricular arrhythmias. Over time, it became apparent that this aggressive approach caused frequent inappropriate therapies for supraventricular tachycardias or self-terminating non-sustained ventricular tachycardias. Observational data suggested that these shocks impaired quality of life, worsened heart failure, and paradoxically increased mortality. MADIT-RIT provided the definitive randomized evidence that programming devices to tolerate brief or slower tachycardias is not only safe but lifesaving.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does an inappropriate ICD shock occur physiologically, and what are the proposed mechanisms by which reducing these shocks leads to a decrease in all-cause mortality?

Key Response

This tests the understanding of ICD sensing errors (e.g., rapid atrial fibrillation, T-wave oversensing) and the adverse physiologic effects of shocks, including direct myocardial injury, sympathetic nervous system surges, and heart failure progression.

Resident

When managing a patient newly implanted with a primary prevention ICD, how should the MADIT-RIT findings influence your initial device programming regarding heart rate cutoffs and detection times?

Key Response

Residents must translate trial data into practical programming. MADIT-RIT established that setting higher rate cutoffs (e.g., >200 bpm) and longer detection intervals allows non-sustained ventricular arrhythmias to self-terminate, avoiding shocks without increasing the risk of syncope.

Fellow

MADIT-RIT focused on primary prevention ICDs. How do the principles of delayed therapy and high-rate cutoffs apply to secondary prevention patients, particularly those who have experienced hemodynamically tolerated VT at rates below 200 bpm?

Key Response

Fellows must recognize the boundary of the trial and understand the nuance of programming for secondary prevention, where patients have known symptomatic VTs that require tailored therapies like anti-tachycardia pacing (ATP) below the 200 bpm threshold.

Attending

MADIT-RIT showed a mortality benefit with less aggressive programming without an increase in syncope. How do you integrate this paradigm shift from 'treat immediately' to 'wait and see' into shared decision-making and patient education regarding ICD shocks?

Key Response

Attendings navigate the clinical paradigm shift. The trial proved that delaying therapy does not significantly increase syncope or sudden death, fundamentally changing practice to prioritize avoiding the iatrogenic harm of inappropriate shocks.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The MADIT-RIT trial was stopped early by the Data and Safety Monitoring Board due to significant efficacy. What are the epidemiological risks of truncating a trial early for benefit, and how might this affect the estimated magnitude of the mortality reduction?

Key Response

Early stopping for benefit can lead to an overestimation of the treatment effect. Methodological critique requires understanding how this affects the precision and generalizability of the hazard ratios reported.

Journal Editor

Given that clinicians programming the devices could not be blinded to the intervention arm, how might this lack of blinding introduce performance bias, and how robust is the secondary endpoint of all-cause mortality against this threat to validity?

Key Response

Editors must look for bias. While all-cause mortality is an objective 'hard' endpoint, unblinded clinicians might alter concurrent heart failure therapies differently based on the programming strategy, potentially confounding the mortality benefit.

Guideline Committee

Based on MADIT-RIT and corroborating trials like ADVANCE III, how should AHA/ACC/HRS guidelines grade the recommendation for high-rate and delayed-therapy programming in primary prevention ICDs?

Key Response

This evidence directly informed the 2015 HRS/EHRA/APHRS/SOLAECE expert consensus, which issued Class I recommendations for programming high-rate cutoffs (>200 bpm) and delayed detection to minimize inappropriate therapies in primary prevention patients.

Clinical Landscape

Noteworthy Related Trials

2004

PainFREE Rx II Trial

n = 634 · Circulation

Tested

Empirical Anti-Tachycardia Pacing (ATP) for Fast VT

Population

Patients with ICDs for primary or secondary prevention

Comparator

Standard shock therapy for Fast VT

Endpoint

Proportion of Fast VT episodes terminated without shock

Key result: ATP safely and effectively terminated the majority of fast VT episodes, significantly reducing the need for painful shocks.

2008

PREPARE Trial

n = 700 · JACC

Tested

Strategic conservative ICD programming

Population

Primary prevention ICD patients

Comparator

Historical controls

Endpoint

Incidence of shocks, syncope, or untreated VT/VF

Key result: Strategic programming significantly reduced the incidence of shocks and morbidities without increasing syncope or sudden death.

2013

ADVANCE III Trial

n = 1,902 · JAMA

Tested

Long detection intervals (30/40 intervals)

Population

Patients receiving a first ICD for primary or secondary prevention

Comparator

Standard detection intervals (18/24 intervals)

Endpoint

Appropriate and inappropriate therapies delivered

Key result: Prolonged detection settings reduced overall therapies and inappropriate shocks without increasing mortality or syncope rates.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis